586P Minimal residual disease (MRD) detection using a tumour naïve circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial.

Authors :: Day, D.
Starus, A.
Gebski, V.
Simes, J.
Hayes, T.
Padinharakam, S.
Strickland, A.H.
Briscoe, K.
Varma, S.
Barnet, M.
Jackson, C.
Horvath, L.G.
Price, T.J.
Tebbutt, N.
Karki, B.
Diakos, C.I.
Chia, J.
Toh, H.C.
Jones, F.S.
Segelov, E.
Source :: Annals of Oncology. 2023 Supplement 2, Vol. 34, pS426-S427. 2p.
Publication Year :: 2023

Subjects :: *CLINICAL trials
*CIRCULATING tumor DNA
*COLORECTAL cancer
*TUMORS

Full Text Access

Tools